Clinipace Expands Leadership Team, Supports New CHALLENGE ACCEPTED Brand
Clinipace , a global full-service contract research organization (CRO), expands its leadership team and launches a new brand identity to support its future growth as a midsized CRO. To better serve its clients, Clinipace is committed to taking a personal approach that focuses on service supported by top CRO talent and technologies.
Dawn Sauro joins Clinipace’s leadership team as chief development officer. In this role, she will be responsible for partnership strategies inclusive of leveraging her relationships within the clinical site community to refine and execute Clinipace’s site relationship strategy. Sauro comes to Clinipace from Sarah Cannon, where she served as president, Development Innovations. She also served in several leadership capacities at inVentiv Health, PRA Health Sciences and PPD.
Sharon Moore , M.D., MPH, MBA, brings more than a decade of experience at a top eight clinical research organization to her role as chief medical officer. In her new position, Moore will increase emphasis on patient data and the early interpretation of that data.
The appointment of Sauro and Moore increases the depth of Clinipace’s operational and therapeutic expertise and its continued investments in new therapeutic areas and analytics capabilities.
“We want to be known as a solutions provider that has a personal interest in our customers’ success,” said Jason Monteleone , CEO at Clinipace. “And, we are making the technology and talent investments to support that type of partnership with our clients.”
Clinipace’s new brand, CHALLENGE ACCEPTED, was developed in support of its commitment to a personalized approach where clients receive a level of collaboration and flexibility not possible with traditional CROs.
For more information, stop by Booth 1700 at the Drug Information Association (DIA) annual meeting, June 24–28, 2018.
At Clinipace , a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. Our personalized services and solutions, local regulatory expertise and therapeutic leadership are designed to face the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach.
Lea Studer, +1 402-366-1752
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
HAS·TO·BE24.4.2019 12:20:11 CEST | Pressemeddelelse
IONITY Fast Charging Network Relies on has·to·be Know-How for the Long Term
CA-FIORANO-SOFTWARE24.4.2019 11:02:11 CEST | Pressemeddelelse
Enterprise Integration Middleware Leader, Fiorano Software, Announces Release of Fiorano Platform 12.0
APTORUM-GROUP24.4.2019 10:32:09 CEST | Pressemeddelelse
Aptorum Group’s Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT™
APTORUM-GROUP-LIMITED24.4.2019 10:32:09 CEST | Pressemeddelelse
Aptorum Group Establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and Unmet Diseases
APTORUM-GROUP24.4.2019 10:17:07 CEST | Pressemeddelelse
Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 2019
EUROPEAN-MORTGAGE-FED24.4.2019 10:05:06 CEST | Pressemeddelelse
The Energy Efficient Mortgages Initiative is Defining the Future: a Greener Future
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum